Therapeutic advances in psychopharmacology
January 1, 2023
Anya Ragnhildstveit, Jeremy Roscoe, Lisa C Bass et al.
49 citations
PTSD has few effective pharmacological treatments, and trauma-focused psychotherapies are limited by provider shortages and low patient engagement, often leading to chronic illness and reduced quality of life. Ketamine, an NMDA receptor antagonist already indicated for major depression with rapid antidepressant effects, shows transdiagnostic potential. A synthesis of clinical evidence—including case reports, chart reviews, open-label studies, and randomized trials—reveals high heterogeneity in presentation and treatment approach but encouraging signals of safety, efficacy, and durability. Future research directions are discussed.
The American journal of drug and alcohol abuse
September 3, 2023
Alan Kooi Davis, Yitong Xin, Nathan Sepeda et al.
29 citations
Combined ibogaine and 5-MeO-DMT assisted therapy produced rapid and large improvements in mental health among trauma-exposed Special Operations Forces Veterans. In a sample of 86 male veterans, self-reported PTSD symptoms, depression, anxiety, insomnia severity, and post-concussive symptoms all significantly decreased from baseline to one-month follow-up. Satisfaction with life, psychological flexibility, and cognitive functioning also significantly improved. The therapeutic effects appeared durable up to six months. The study was a prospective clinical program evaluation conducted in Mexico, and the authors call for future controlled research to confirm these findings.
The American journal of bioethics : AJOB
January 1, 2025
Logan Neitzke-Spruill, Caroline Beit, Lynnette A Averill et al.
19 citations
The FDA rejected Lykos Therapeutics' application for MDMA-assisted therapy for PTSD in August 2024, partly due to a highly publicized case of alleged sexual misconduct by an unlicensed therapist during a Phase 2 trial. Several other cases of misconduct by facilitators at psychedelic retreats have raised questions about whether physical contact is ever appropriate during psychedelic-assisted therapy. Drawing on research about supportive touch in other clinical settings and considering features of psychedelics that increase the potential for harm, the authors advocate for a precautionary approach to harm-reduction while arguing that supportive touch should not be entirely discarded.
Military psychology : the official journal of the Division of Military Psychology, American Psychological Association
January 1, 2024
Stacey B Armstrong, Yitong Xin, Nathan D Sepeda et al.
19 citations
Among 45 U.S. Special Operations Forces Veterans with risky alcohol use who completed ibogaine and 5-MeO-DMT treatment in Mexico, alcohol use dropped substantially from an average of 7.2 drinks per drinking day before treatment to 3.6 at one month and 4.0 at six months post-treatment. At one month, 24% were abstinent, 33% were non-risky drinkers, and 42% still risky drinkers; by six months, 16% were abstinent, 31% non-risky, and 53% risky. Responders (abstinent or non-risky) showed very large improvements in PTSD symptoms and cognitive functioning compared to non-responders, while demographics did not differ. The findings suggest psychedelic-assisted therapy may help those with complex trauma and alcohol misuse who have not responded to traditional treatments.
iScience
January 16, 2026
Amir Valizadeh, John D Roache, Xinyu Zhang et al.
2 citations
Post-traumatic stress disorder varies greatly in its clinical and biological features, making treatment difficult. The largest randomized trial of ketamine for PTSD found no overall benefit over placebo, highlighting the need to identify which patients might respond. Using pre-treatment blood DNA methylation profiles and clinical data from that trial, machine learning models predicted treatment response. A model based on 1,208 methylation sites outperformed models using only clinical variables, and combining both data types improved accuracy further. The methylation-derived score identified responders with 92.9% accuracy. Predictive methylation sites were near genes involved in glutamatergic signaling, immune regulation, and known PTSD risk loci, suggesting peripheral DNA methylation patterns can guide precision pharmacotherapy for PTSD.